Glimepirin indusoima SIADH tapaus

http://www.diabet-metabolism.com/article/S1262-3636(14)00195-5/abstract

H. Adachi

,

H. YanaiPress enter key for correspondence informationPress enter key to Email the author

Department of Internal Medicine, National Center for Global Health and Medicine, Kohnodai Hospital, Chiba, Japan

DOI: http://dx.doi.org/10.1016/j.diabet.2014.11.010

• Abstract

• Full Text
• References

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is characterized by hyponatraemia (serum Na < 135 mmol/L) without dehydration, increased renal excretion of sodium (urinary Na > 20 mmol/L), detectable plasma antidiuretic hormone (ADH) in spite of hyponatraemia, low plasma osmolality (< 280 mOsm/kg) and high urinary osmolality (> 300 mOsm/kg) in the presence of normal renal and adrenal function. Here, we describe the first case of SIADH induced by the third-generation sulphonylurea glimepiride.

Keywords:

Glimepiride, Hyponatraemia, Syndrome of inappropriate antidiuretic hormone secretion, Type 2 diabetes

Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice

Diabetes & Metabolism, Vol. 41, Issue 3

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

Diabetes & Metabolism, Vol. 40, Issue 6

Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control

Diabetes & Metabolism, Vol. 41, Issue 3

Incretin-based therapy and pancreatic beta cells

Diabetes & Metabolism, Vol. 40, Issue 6

Hypoglycaemia requiring medical assistance in patients with diabetes: A prospective multicentre survey in tertiary hospitals

Diabetes & Metabolism, Vol. 41, Issue 2

View All